Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL

At the American Society of Hematology (ASH) 2025 meeting, updated results from the phase 2 EPCORE NHL‑2 (NCT04663347) trial highlighted the potential of epcoritamab combined with chemotherapy to improve outcomes for patients with newly…